Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 4/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724002 | 0.93 | LMNA (0.40) | LMNASMN1; SMN2RXRANR1H2SLC2A1 | |
| SCHEMBL21724004 | 0.88 | L3MBTL1 (0.35) | SLC2A1TRPM8LTB4R2L3MBTL1NR1H3 | |
| SCHEMBL21723770 | 0.81 | CNR2 (0.35) | LMNASMN1; SMN2SLC2A1L3MBTL1MEN1 | |
| SCHEMBL29765181 | 0.75 | L3MBTL1 (0.41) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL21741216 | 0.75 | L3MBTL1 (0.41) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL24610154 | 0.73 | APLNR (0.36) | SLC2A1L3MBTL1MEN1KMT2A | |
| SCHEMBL29765130 | 0.73 | APLNR (0.36) | SLC2A1L3MBTL1MEN1KMT2A | |
| SCHEMBL14731889 | 0.69 | TMEM97 (0.58) | LMNA | |
| SCHEMBL24291657 | 0.67 | ALDH1A1 (0.43) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL21723771 | 0.67 | KMT2A (0.35) | LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897898-B2 | Pyridine macrocycle compounds as ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3837265-B1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3837265-B1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210300946-A1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-09-30 | — | — | US | disclosed |
| EP-3837265-A1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | Biogen MA Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020036946-A1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036946-A1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897898-B2 | Pyridine macrocycle compounds as ASK1 inhibiting agents | MAP3K1, MAP3K19, MAP3K20 | LMNA 1313/4885SMN1; SMN2 1085/4885RXRA 2448/4885 |
| US-20210300946-A1 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS | MAP3K1, MAP3K19, MAP3K20 | LMNA 1313/4885SMN1; SMN2 1085/4885RXRA 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.